These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15105061)

  • 1. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
    Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
    Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
    Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
    Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study.
    Magnusdóttir EM; Bjarnadóttir RI; Onundarson PT; Gudmundsdóttir BR; Geirsson RT; Magnusdóttir SD; Dieben TO
    Contraception; 2004 Jun; 69(6):461-7. PubMed ID: 15157790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid profile in women over 35 years old using triphasic combined oral contraceptives.
    Aldrighi JM; Petta CA; Bahamondes L; Caetano ME; Martinez TR; De Lima GR
    Contraception; 2004 May; 69(5):395-9. PubMed ID: 15105062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism.
    Barreiros FA; Guazzelli CA; Barbosa R; Torloni MR; Barbieri M; Araujo FF
    Contraception; 2011 Aug; 84(2):155-9. PubMed ID: 21757057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower hormone dosage with improved cycle control.
    Vree M
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
    Oddsson K; Leifels-Fischer B; de Melo NR; Wiel-Masson D; Benedetto C; Verhoeven CH; Dieben TO
    Contraception; 2005 Mar; 71(3):176-82. PubMed ID: 15722066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
    Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
    Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular growth during contraceptive pill or vaginal ring treatment depends on the day of ovulation in the pretreatment cycle.
    Duijkers IJ; Verhoeven CH; Dieben TO; Klipping C
    Hum Reprod; 2004 Nov; 19(11):2674-9. PubMed ID: 15319379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete and robust ovulation inhibition with NuvaRing.
    Killick S
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():13-8; discussion 37-9. PubMed ID: 12659397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
    Roumen FJ; Dieben TO
    Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism.
    Scharnagl H; Petersen G; Nauck M; Teichmann AT; Wieland H; März W
    Contraception; 2004 Feb; 69(2):105-13. PubMed ID: 14759614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage.
    Verhoeven CH; Dieben TO
    Contraception; 2004 Mar; 69(3):197-9. PubMed ID: 14969666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.